Inherited variation in the ATP-binding cassette transporter ABCB1 and survival after chemotherapy for stage III-IV lung cancer

Journal of Thoracic Oncology

Volumn 9, Issue 9, 2014, Pages 1264-1271

  Weissfeld, Joel L ^a,b   Diergaarde, Brenda ^a,b   Nukui, Tomoko ^c   Buch, Shama ^c   Pennathur, Arjun ^c   Socinski, Mark A ^c   Siegfried, Jill M ^c   Romkes, Marjorie ^c  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC METAL COMPLEX; GLUTATHIONE TRANSFERASE P1; MULTIDRUG RESISTANCE PROTEIN 1; TAXANE DERIVATIVE; ABCB1 PROTEIN, HUMAN; DNA; MULTIDRUG RESISTANCE PROTEIN;

ADULT; AGED; ALLELE; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER STAGING; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENOTYPE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; CARCINOMA, NON-SMALL-CELL LUNG; EPIDEMIOLOGY; FOLLOW UP; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; MORTALITY; RETROSPECTIVE STUDY; SURVIVAL RATE; TRENDS; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALLELES; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; P-GLYCOPROTEINS; PENNSYLVANIA; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84906218732     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000262     Document Type: Article

References (33)

1. Surveillance E and End Results (SEER) Program (www.seer.cancer. gov). SEER*Stat Database: Incidence - SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2012 Sub (1973-2010 varying) - Linked To County Attributes - Total U.S., 1969-2011 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2013, based on the November 2012 submission.
2. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899-909.
3. Buch SC, Diergaarde B, Nukui T, et al. Genetic variability in DNA repair and cell cycle control pathway genes and risk of smoking-related lung cancer. Mol Carcinog 2012;51(Suppl 1):E11-E20.
4. Marsh S, McLeod H, Dolan E, et al. Platinum pathway. Pharmacogenet Genomics 2009;19:563-564.
5. Oshiro C, Marsh S, McLeod H, Carrillo MW, Klein T, Altman R. Taxane pathway. Pharmacogenet Genomics 2009;19:979-983.
6. Fritz A, Percy C, Jack A, et al. (Eds). ICD-O: International Classification of Diseases for Oncology. 3rd ed. Geneva, Switzerland: World Health Organization, 2000.
7. Greene FL, Page DL, Fleming ID, et al. (Eds). AJCC Cancer Staging Manual. 6th ed. New York: Springer, 2002.
8. Facility Oncology Registry Data Standards: Revised for 2011. American College of Surgeons Commission on Cancer, 2011.
9. Thornton M, O'Connor L (Eds). Standards for Cancer Registries Volume II: Data Standards and Data Dictionary, Record Layout Version 12. 14th ed. Springfield, IL: North American Association of Central Cancer Registries, February 2009, rev. August 2009.
10. Leschziner GD, Andrew T, Pirmohamed M, Johnson MR. ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J 2007;7:154-179.
11. Choy H, Pyo H, Kim JS, MacRae R. Role of taxanes in the combined modality treatment of patients with locally advanced non-small cell lung cancer. Expert Opin Pharmacother 2001;2:963-974.
12. Ramalingam S, Belani CP. Taxanes for advanced non-small cell lung cancer. Expert Opin Pharmacother 2002;3:1693-1709.
13. Isla D, Sarries C, Rosell R, et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 2004;15:1194-1203.
14. Han JY, Lim HS, Yoo YK, et al. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer 2007;110:138-47.
15. Pan JH, Han JX, Wu JM, Sheng LJ, Huang HN, Yu QZ. MDR1 single nucleotide polymorphisms predict response to vinorelbine-based chemotherapy in patients with non-small cell lung cancer. Respiration 2008;75:380-385.
16. Gandara DR, Kawaguchi T, Crowley J, et al. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol 2009;27:3540-3546.
17. Pan JH, Han JX, Wu JM, Huang HN, Yu QZ, Sheng LJ. MDR1 single nucleotide polymorphism G2677T/A and haplotype are correlated with response to docetaxel-cisplatin chemotherapy in patients with non-smallcell lung cancer. Respiration 2009;78:49-55.
18. Chen S, Huo X, Lin Y, et al. Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients. Int J Hyg Environ Health 2010;213:140-145.
19. Viñolas N, Provencio M, Reguart N, et al. Single nucleotide polymorphisms in MDR1 gene correlates with outcome in advanced non-smallcell lung cancer patients treated with cisplatin plus vinorelbine. Lung Cancer 2011;71:191-8.
20. Yan PW, Huang XE, Yan F, Xu L, Jiang Y. Influence of MDR1 gene codon 3435 polymorphisms on outcome of platinum-based chemotherapy for advanced non-small cell lung cancer. Asian Pac J Cancer Prev 2011;12:2291-2294.
21. Campa D, Müller P, Edler L, et al. A comprehensive study of polymorphisms in ABCB1, ABCC2 and ABCG2 and lung cancer chemotherapy response and prognosis. Int J Cancer 2012;131:2920-2928.
22. Dogu GG, Kargi A, Turgut S, et al. MDR1 single nucleotide polymorphism C3435T in Turkish patients with non-small-cell lung cancer. Gene 2012;506:404-407.
23. Wei HB, Lu XS, Shang LH, et al. Polymorphisms of ERCC1 C118T/C8092A and MDR1 C3435T predict outcome of platinum-based chemotherapies in advanced non-small cell lung cancer: a meta-analysis. Arch Med Res 2011;42:412-420.
24. Sato Y, Yamamoto N, Kunitoh H, et al. Genome-wide association study on overall survival of advanced non-small cell lung cancer patients treated with carboplatin and paclitaxel. J Thorac Oncol 2011;6:132-138.
25. Wu X, Ye Y, Rosell R, et al. Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy. J Natl Cancer Inst 2011;103:817-825.
26. Hu L, Wu C, Zhao X, et al. Genome-wide association study of prognosis in advanced non-small cell lung cancer patients receiving platinum-based chemotherapy. Clin Cancer Res 2012;18:5507-5514.
27. Herraez E, Gonzalez-Sanchez E, Vaquero J, et al. Cisplatin-induced chemoresistance in colon cancer cells involves FXR-dependent and FXR-independent up-regulation of ABC proteins. Mol Pharm 2012;9:2565-2576.
28. Zhang DM, Shu C, Chen JJ, et al. BBA, a derivative of 23-hydroxybetulinic acid, potently reverses ABCB1-mediated drug resistance in vitro and in vivo. Mol Pharm 2012;9:3147-3159.
29. Gibalová L, Sereš M, Rusnák A, et al. P-glycoprotein depresses cisplatin sensitivity in L1210 cells by inhibiting cisplatin-induced caspase-3 activation. Toxicol In Vitro 2012;26:435-444.
30. Chang A. Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer 2011;71:3-10.
31. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000;97:3473-3478.
32. Fung KL, Gottesman MM. A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim Biophys Acta 2009;1794:860-871.
33. Vivona D, Bueno CT, Lima LT, et al. ABCB1 haplotype is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib. Blood Cells Mol Dis 2012;48: 132-136.